The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia

Modern cancer therapies increased the survival rates of acute myeloid leukemia (AML) patients tremendously. However, the complexity of the disease and the identification of new targets require the adaptation of treatment protocols to reduce side effects and increase benefit for the patients. One key...

Descripción completa

Detalles Bibliográficos
Autores principales: Wellbrock, Jasmin, Behrmann, Lena, Muschhammer, Jana, Modemann, Franziska, Khoury, Kais, Brauneck, Franziska, Bokemeyer, Carsten, Campeau, Eric, Fiedler, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592969/
https://www.ncbi.nlm.nih.gov/pubmed/34333666
http://dx.doi.org/10.1007/s00277-021-04602-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592969/
https://www.ncbi.nlm.nih.gov/pubmed/34333666
http://dx.doi.org/10.1007/s00277-021-04602-z

Ejemplares similares